A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer

LESSONS LEARNED: Concurrent ETBX‐011, ETBX‐051, and ETBX‐061 can be safely administered to patients with advanced cancer. All patients developed CD4(+) and/or CD8(+) T‐cell responses after vaccination to at least one tumor‐associated antigen (TAA) encoded by the vaccine; 5/6 patients (83%) developed...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncologist
Prif Awduron: Gatti‐Mays, Margaret E., Redman, Jason M., Donahue, Renee N., Palena, Claudia, Madan, Ravi A., Karzai, Fatima, Bilusic, Marijo, Sater, Houssein Abdul, Marté, Jennifer L., Cordes, Lisa M., McMahon, Sheri, Steinberg, Seth M., Orpia, Alanvin, Burmeister, Andrea, Schlom, Jeffrey, Gulley, James L., Strauss, Julius
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley & Sons, Inc. 2019
Pynciau:
Clinical Trial Results
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7288633/
https://ncbi.nlm.nih.gov/pubmed/31594913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0608
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg